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OtotoxicityAbstract Despite the risk of permanent ototoxic effects, aminoglycosides remain commonly uti-
lized antibiotics worldwide due to low cost and efficiency in treating severe infections. Over the last
two decades, mitochondrial mutations have been shown to enhance the likelihood of ototoxic
injury. In particular the 1555A>Gmutation in the mitochondrial geneMTRNR1 has been strongly
associated with the onset of aminoglycoside-induced deafness; though pinning down the exact
mechanism of action has thus far been elusive. Clinically aminoglycoside-induced deafness has been
characterized by variation in the degree of hearing loss, which has prompted an investigation into
genetic modifiers. To date, several putative mutations have been categorized as contributing factors
to the onset of deafness with no single variation being sufficient to bring about hearing loss. Mean-
while current methods to mitigate the risk of ototoxic injury are in various stages of development.
Efforts to alter the molecular structure of aminoglycosides have shown a potential path to reducing
ototoxicity while preserving antibacterial properties, but these drugs are not clinically available. On
the other hand, application of preemptive audiometry provides the most readily available method to
both monitor and reduce the extent of aminoglycoside-induced deafness.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288
2. Mechanism of aminoglycoside ototoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288
3. Increased susceptibility to aminoglycoside ototoxicity due to mitochondrial mutations . . . . . . . . . . . . . . . . . . . . . . 288
4. Genetic modifiers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 290
5. Current methods of reducing ototoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 290
6. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 290
Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291
288 J. Foster, M. TekinAcknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2911. Introduction
Hereditary hearing loss is the most common sensory problem,
affecting 1 and 1000 newborns [1]. While around half of con-
genital deafness is explained genetically, hearing loss has also
been linked to environmental factors such as in utero contrac-
tion of cytomegalovirus and antibiotics [2]. Originally devel-
oped in the 1940’s aminoglycosides (AG) have been effective
in treating gram-negative bacterial infections [3]. Unfortu-
nately though, systemic administration of AGs can lead to
both nephrotoxicity and ototoxicity [4,5]. In populations
where AGs were commonly prescribed familial inheritance of
ototoxicity became evident. Matrilineal inheritance of
aminoglycoside-induced deafness (AID) was a defining charac-
teristic in several of these families, which suggested mitochon-
drial involvement [6].
Currently the genetic mutations most strongly associated
with AID are 1555A>G and 1494C>T in the mitochondrial
geneMTRNR1, which codes for the mitochondrial 12S riboso-
mal subunit [7,8]. These mitochondrial positions map to the
corresponding 1409–1491 base pairing in bacteria, which are
the AG binding sites on the 16S ribosome subunit [9]. Several
additional variations in mitochondrial tRNA genes have been
associated with AID and non-syndromic hearing loss [10–12],
though biochemical analysis of these variations suggests many
are not sufficient to generate the hearing loss phenotype. While
the effect of systemic AG administration in individuals carrying
a mitochondrial tRNA gene mutation is not well established, it
is clear that genetic defects in the mitochondrialMTRNR1 gene
at positions 1555 and 1494 facilitate AG-induced deafness [13].
Modifiers in the nuclear genome may provide an explana-
tion for familial cases of non-syndromic deafness involving
the 1555A>G mitochondrial mutation and absence of AG
treatment. The nuclear gene TRMU has been identified as
one such modifier, as a missense mutation in TRMU was
shown to compromise tRNA metabolism. Reduction of tRNA
metabolism in combination with the reduction of accurate pro-
tein synthesis caused by the 1555A>G mutation may be suffi-
cient to cause the hearing loss phenotype, though this is yet to
be fully elucidated [14].
As AGs continue to be prescribed to treat common infec-
tions around the world, reducing or removing the potential
for ototoxicity holds significant clinical value. While concomi-
tant treatment of AGs and antioxidants yields moderate pro-
tective properties, recent research on structurally unique AGs
shows promise in reducing ototoxicity [15–18]. Increasing the
size of AGs prohibits entry to the cytosol of cochlear hair cells
while maintaining its potent antibacterial properties. As the
physical properties of the cationic channels of hair cells are fur-
ther characterized, these data may lead to improvements in AG
alteration, potentially removing the concern of ototoxicity.
2. Mechanism of aminoglycoside ototoxicity
Localization of aminoglycosides to hair cells begins by cross-
ing the blood-endolymph barrier [19]. Once in the endolymphAGs transverse the apical membrane of hair cells via the
mechanoelectrical transducer (MET) channel or other cationic
channels [20–23]. AG entrance through the MET channel was
initially proposed after the detection of AGs at the tip of the
stereocilia prior to observing AG in the cytosol of hair cells
[24]. Further investigation revealed the opening of the channel
measures 1.25 nm in diameter which is sufficient for the pas-
sage of AGs [25]. Alharazneh et al. has also shown that AGs
reduce the transduction current pointing to the involvement
of the MET channel [21]. Moreover, various concomitant fac-
tors have been shown to potentiate AID. Noise induces the
open state of the MET channel leading to an increased concen-
tration of AGs in the hair cell cytosol [26]. Hirose et al. reports
the combined administration of aminoglycosides with loop
diuretics exacerbates ototoxic injury in mice when compared
with controls and mice injected only with aminoglycosides
[27]. Cochlear uptake of aminoglycosides is also increased by
endotoxemia-induced inflammation [28]. The unidirectional
MET channel compounds the effect of these additional poten-
tiating factors, as AGs are unable to move back to the endo-
lymph leading to higher concentration in the hair cell cytosol
[23].
Once in hair cell cytosol AGs interact with mitochondrial
12S ribosomal subunit causing inaccurate translation of mito-
chondrial proteins. The downstream implication of faulty pro-
tein synthesis is eventual cell death either through caspase-
mediated or non-caspase-mediated apoptosis [22]. Addition-
ally, AG interaction with iron species has been shown to pro-
duce reactive oxygen species (ROS), which also leads to cell
death through apoptosis [29]. Previous in vitro experiments
have shown an alteration in antioxidant defense system in mel-
anocytes induced by aminoglycosides, which may be an addi-
tional contributing factor in the onset of ototoxicity [30].
Rizzi et al. has also shown a clear progression of hair cell death
originating at the basal turn and moving toward apical turn of
the cochlea [31]. This progression moves in line with the onset
of deafness, as high frequency loss is observed before the loss
of lower frequencies.3. Increased susceptibility to aminoglycoside ototoxicity due to
mitochondrial mutations
The baseline incidence of cochleotoxic effects following the
administration of systemic AGs has previously been reported
between 2% and 25%, and has been known to fluctuate
depending on the drug administered [31,32]. Amikacin, Gen-
tamicin, and Tobramycin produce ototoxic effects at a rate
of 5%, 8%, and 14% respectively [32]. The incidence of AID
increases to 17–33% in cases involving genetic variations
[22]. In particular the 1555A>G and 1494C>T mutations in
the MTRNR1 gene have been shown to facilitate the binding
of AGs to the 12S ribosomal subunit [13].
Prezant et al. initially sequenced the mitochondrial genome
in three families with maternally inherited AID revealing the
1555A>G variation in the mitochondrial MTRNR1 gene [7].
Over the last two decades 1555A>G has been identified as
Table 1 1555A>G frequencies found during mitochondrial screening of hearing impaired people in various different populations.
Country City or
Province
1555A>G/Families Screened Controls AID cases in
Cohort
Homoplasmy Type of
Deafness
Reference
European
Cohort
– 18/9371 (0.19%) 1/520
population level
– – – – [50]
China Xiamen 6/155 (3.87%) 0/– 4 Homoplasmic NSHL [51]
Finland – 1/103 (0.97%) –/– – – SHL and
NSHL
[52]
China – 10/538 (1.85%) 0/256 10 Homoplasmic NSHL [53]
China – 36/301 (12%) –/– – – Familial
NSHL
[54]
China Hubei 95/813 (11.68%) 0/126 78 Homoplasmic HL [55]
Taiwan Zhongzheng 1/1017 (0.09%) –/– – Homoplasmic Newborn
screening
[56]
Greece – 2/513 (0.38%) –/– – – Various [57]
Morocco – 3/84 (3.57%) 0/100 0 Homoplasmic NSHL [58]
Turkey – 3/168 (1.8%) – – – NSHL [59]
China – 5/284 (1.76%) 0/200 5 – NSHL [60]
Poland – 1/250 (0.4%) –/– – – Unknown [61]
Belgium – 2/466 (0.42%) 0/400 1 Homoplasmic NSHL [62]
Korea – 2/227 (0.88%) 0/217 – Heteroplasmic/
Homoplasmic
NSHL [63]
Italy – 9/167 (5.38%) –/– 9 Homoplasmic NSHL [64]
China Gansu 44/514 (8.56%) 0/117 23 – NSHL [65]
United
States
– 7/41 (17%) – – – NSHL [66]
Taiwan – 10/315 (3.17%) –/120 2 Homoplasmic NSHL [67]
China – 8/60 (13.33%) 0/354 60 Homoplasmic AID [68]
Spain – 69/443 (15.57%) –/100 24 – NSHL [69]
Tunisia – 1/100 (1%) 0/100 0 – NSHL [70]
Brazil – 5/204 (2.45%) 0/300 1 – Various
NSHL
[71]
Spain – 42/209 (20%) 0/200 – – NSHL [72]
United
Kingdom
– 2/80 (2.5%) –/– – – NSHL [73]
United
States
Cincinnati 1/164 (0.6%) –/226 0 Homoplasmic NSHL [74]
Spain – 105/648 (16.2%) –/– 2 Various NSHL [75]
Indonesia Sulawesi 4/75 (5.33%) 0/100 – Homoplasmic NSHL [76]
Denmark – 2/85 (2.4%) – – – NSHL [77]
Finland – 2/117 (1.7%) – – – NSHL [78]
Germany – 1/139 (0.7%) 0/160 – – NSHL [79]
Poland – 3/125 (2.4%) 0/89 – – NSHL [79]
Mongolia – 37/480 (7.7%) 0/389 – – NSHL [80]
Poland – 9/250 (3.6%) 0/250 7 Homoplasmic NSHL/AID [81]
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This base-pair change maps to a conserved position within
the A-site of the 12S small ribosomal subunit, which is the
homologous decoding region AGs bind to on the bacterial
16S ribosomal subunit [9]. The aberrant C–G base-pairing
alters the secondary structure of the mitochondrial 12S small
rRNA causing it to take on more of the bacterial 16S small
rRNA characteristic [9]. Moreover, these structural changes
have been shown to result in a higher affinity for AGs in E.coli
carrying the corresponding mutation at the 1491 position when
compared with controls [33].
The 1494C>T mutation has been shown to cause both
non-syndromic hearing loss and AID, but the occurrence of
this mutation has thus far been limited to the Chinese and
Spanish populations and is characterized by phenotypic varia-
tion [8,34]. Nonetheless, the 1494C>T change occurs at thesame conserved base pairing as 1555A>G in the mitochon-
drial 12S ribosomal subunit. Lymphoblastoid cell lines derived
from a patient who carried this particular mutation showed
reduced oxygen consumption and growth when exposed to
AGs [8].
Outside of the MTRNR1 gene, several reports show muta-
tions occurring in mitochondrial tRNA genes [35]. While a
strong causative link between mutations in mitochondria
tRNA genes and hearing loss has yet to be established due
to inconsistency in mutation segregation and penetrance, pre-
viously conducted in vitro experiments show reduced metabo-
lism of mitochondrial tRNA in cell lines carrying certain
mutations. Lymphoblastoid cell lines derived from patients
with 7445A>C, 7511T>C or 7505T>C have shown a clear
reduction in steady-state tRNA [36–38]. Given the multifacto-
rial nature of mitochondrial disease, concomitant occurrence
290 J. Foster, M. Tekinof several genetic defects such as these tRNA mutations and
the more common 1555A>G mutation may produce sufficient
stress to result in the observed hearing loss phenotype.
Identification of additional mitochondrial variations that
increase sensitivity to AGs holds clinical value, as it will allow
for the development of effective screening panels. A recent
comprehensive meta-analysis found a significant association
of 10 previously reported variations not including 1555A>G
and hearing loss [39]. These include 839A>G, 961delTinsC
(2_7) (Significant only in European subpopulation),
988G>A, 1009C>T, 1095T>C, 1107T>C, 1382A>C,
1494C>T, 1557A>C and 15927G>A. When considering
AG exposure only five of these variations were significantly
associated with AID: 839A>G, 1095T>C, 1107T>C,
1494C>T, 1555A>G.4. Genetic modifiers
Variation in the degree of hearing loss in patients with
1555A>G or 1494T>C points to the involvement of addi-
tional environmental factors or genetic modifiers [9]. Previous
reports have proposed a >50% decrease in mitochondria pro-
tein synthesis will decrease cellular respiration and growth [40].
The 1555A>G and 1494C>T mutations have been shown to
reduce protein synthesis by 34% and 40% in cybrid cell
lines; a model that controls for nuclear modifiers by combining
the nuclear material from a wild-type cell with the mitochon-
dria isolated from patients carrying a mutation [41,42]. Both
1555A>G and 1494C>T mutations alone are not sufficient
to meet the 50% reduction threshold, and therefore subsequent
respiration and growth stress are unlikely to generate the hear-
ing loss phenotype [41]. While administration of AGs in a
patient with 1555A>G or 1494C>T mutation leads to hear-
ing loss, the combination of nuclear variation and either
1555A>G or 1494C>T may yet prove to be pathogenic.
Guan et al. identified TRMU as a modulating gene in sev-
eral families carrying the 1555A>G mutation [14]. TRMU
codes for the protein 5-methylaminomethyl-2-thiouridylate-m
ethyltransferase, which plays a role in the modification of
tRNAs. A missense mutation at position c.28G>T leads to
the amino acid change p.A10S, which is a highly conserved
region of the protein. This mutation co-segregated with hear-
ing loss in one branch of a large Arab-Israeli family and six
Spanish families who also have 1555A>G. The c.28G>T
mutation occurs with high frequency in both Chinese and
Spanish populations, which indicated that the mutation is unli-
kely to cause hearing loss alone. Further functional analysis of
the c.28G>T mutation revealed loss of enzymatic activity, and
subsequent reduction in tRNA metabolism. Therefore, combi-
nation of reduced tRNA metabolism and the loss of function-
ality at A-site of the small 12S rRNA resulted in a protein
synthesis rate less than 50%, which suggests that high
energy-consuming cochlear hair cells may be damaged. How-
ever, complete co-segregation of the TRMU variation and
the 1555A>G in patients with hearing loss was absent from
this study.
GJB2 is the most common cause of congenital profound
hearing loss in many populations [43]. GJB2 codes for the pro-
tein connexin 26 a gap junction protein, which regulates ion
concentration in the endolymph and subsequently allows for
normal hearing [43]. Reduced production of ATP caused bythe 1555A>G mutation has been suggestively linked with cel-
lular inability to efficiently turnover the gap-junction protein
coded for by GJB2 [44]. However, a previous report investigat-
ing the two common GJB2 mutations c.35delG and c.235delC
in association with 1555A>G revealed no strong correlation
between genotype and phenotype [45].
Additionally, comparison of 10 Chinese haplogroups con-
taining the 1555A>G mutation has also revealed a significant
difference in penetrance when certain haplogroups were com-
pared to the average of the collective [46]. This provides addi-
tional evidence that the mitochondrial genetic environment
plays a role in the eventual phenotypic presentation.
A limited number of studies have characterized variations
in the nuclear genome that co-segregate with the 1555A>G
mutation, and no study has utilized next-generation sequenc-
ing to elucidate the involvement of nuclear background to
date. Given that both 1555A>G and 1494C>T do not reduce
the mitochondria protein synthesis below the 50% threshold to
compromise cellular respiration, uncovering a potential modi-
fication role nuclear genes play provides an interesting topic
for future study. In particular screening the nuclear genome
in future studies may provide mechanistic insights for rare
cases in which patients carrying a homoplasmic 1555A>G
mutation and has been repeatedly treated with aminoglyco-
sides, but experiences no deafness [47].
5. Current methods of reducing ototoxicity
Increased concentration of ROS within hair cells following sys-
temic administration of AGs has led to investigating antioxi-
dants as means to mitigate ototoxicity. While studies have
shown reduction of ototoxicity in vitro, complete protection
from ototoxic injury has not been achieved in humans [22].
Although other mitigating agents such as Aspirin have been
successful in reducing the ototoxicity, serious side-effects
including higher incidence of gastrointestinal bleeding offset
the benefits [48]. Huth et al. has directly altered the size of
AGs, leveraging the 1.25 nm pore size of the MET channel
[15]. Increasing the size the AG molecule precludes entrance
to the hair cell cytosol, while preserving the intended antibac-
terial properties. The clear advantage to this approach is
administration of a single high-efficacy compound, as opposed
to supplementing a previously derived AG with antioxidants.
Proactive utilization of both audiometry and genetic screen-
ing prior to AG administration will allow for early detection
and quicker clinical response. As the basal turn of the cochlea
is more susceptible to ototoxic injury, early and regular screen-
ing of high-frequency deafness will allow physicians to stop
treatment and exercise other treatment options [49]. Prior to
administering AGs family history of deafness should be evalu-
ated. If a matrilineal inheritance pattern is uncovered the mito-
chondrial genome should be screened for the presence of
mutations associated with AID. Finally, newborn screening
for the DNA variants associated with AID, would determine
individuals at risk before they get exposed to AGs.
6. Conclusion
As aminoglycosides continue to be utilized for the treatment of
gram-negative bacterial infections, consideration of preexisting
genetic defects may prove to be clinically valuable. To date,
Aminoglycoside induced ototoxicity associated with mitochondrial DNA mutations 291hypersensitivity to AGs is facilitated by the 1555A>G and
1494C>T mitochondrial mutations. While several additional
mitochondrial variations may eventually prove to play an inte-
gral role in the onset of hearing loss, the underlying biochem-
ical basis has yet to be fully elucidated. Nonetheless, the
current characterization of the MET channel has already led
to research on altering the structure of AGs, which may pro-
vide a method to alleviate concern for potential ototoxicity.
Meanwhile, clinicians should continue to consider the
increased susceptibility that comes from genetic defect, as the
combination of AGs and genetic defect could result in suffi-
cient mitochondrial stress to cause hearing loss.Conflict of interest
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